RxDoctor Payments Data

Szymon Krzyzanowski, MD

Family Medicine · Youngstown, OHNPI 1134384993

Payments from drug & device makers

$7,445in general payments, 2019–2025

Across 455 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$763
  • Novo Nordisk$683
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$534
  • Lilly USA, LLC$528
  • AstraZeneca$451
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,439100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,445 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$53,863
Medicare patients
212
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$113,214
OzempicSemaglutide53$87,849
JardianceEmpagliflozin54$77,433
FarxigaDapagliflozin Propanediol26$34,343
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$28,723
TrulicityDulaglutide22$23,563
XareltoRivaroxaban14$21,948
QuliptaAtogepant12$14,556
Tresiba Flextouch U-200Insulin Degludec14$14,091
EntrestoSacubitril/Valsartan13$13,189
MyrbetriqMirabegron20$9,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$6,503
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,091
Atorvastatin Calcium442$3,653
Gabapentin144$2,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$417$114,607121 claims
Novo NordiskOzempic$683$87,84953 claims
Boehringer IngelheimJardiance$141$77,43354 claims
AstraZenecaFarxiga$451$34,34326 claims
GSKTrelegy Ellipta$271$28,72331 claims
Lilly USA, LLCTrulicity$528$23,56322 claims
Johnson & JohnsonXarelto$240$21,94814 claims
AbbVieQulipta, Synthroid$1,157$15,98345 claims
NovartisEntresto$300$13,18913 claims
Astellas Pharma US IncMyrbetriq$92$9,33120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →